Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionVITNX - Vanguard Institutional Total Stock Market Index Fund Institutional Shares
Latest Disclosed Ownership56,623 shares
Latest Disclosed Value $ 1,401,985
VITNX - Vanguard Institutional Total Stock Market Index Fund Institutional Shares ownership in CPRX / Catalyst Pharmaceuticals, Inc.

On May 28, 2026 - VITNX - Vanguard Institutional Total Stock Market Index Fund Institutional Shares filed a NPORT-P form disclosing ownership of 56,623 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $1,401,985 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 26, 2026 disclosing 56,623 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $1,783,058 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-28 2026-03-31 NP CATALYST PHARMAC EC US14888U1016 56,623 0 0.00 1,402 6.06 0.0046
2026-02-26 2025-12-31 NP CATALYST PHARMAC EC US14888U1016 56,623 0 0.00 1,322 18.48 0.0042
2025-11-25 2025-09-30 NP CATALYST PHARMAC EC US14888U1016 56,623 -1,727 -2.96 1,115 -11.93 0.0036
2025-08-27 2025-06-30 NP CATALYST PHARMAC EC US14888U1016 58,350 -2,125 -3.51 1,266 -13.64 0.0042
2025-05-28 2025-03-31 NP CATALYST PHARMAC EC US14888U1016 60,475 4,122 7.31 1,467 24.66 0.0054
2025-02-28 2024-12-31 NP CATALYST PHARMAC EC US14888U1016 56,353 -5,903 -9.48 1,176 -4.93 0.0041
2024-11-26 2024-09-30 NP CATALYST PHARMAC EC US14888U1016 62,256 -4,283 -6.44 1,238 20.10 0.0039
2024-08-27 2024-06-30 NP CATALYST PHARMAC EC US14888U1016 66,539 0 0.00 1,031 -2.83 0.0032
2024-05-29 2024-03-31 NP CATALYST PHARMAC EC US14888U1016 66,539 -3,041 -4.37 1,061 -9.32 0.0034
2024-02-29 2023-12-31 NP CATALYST PHARMAC EC US14888U1016 69,580 7,836 12.69 1,170 62.14 0.0037
2023-11-28 2023-09-30 NP CATALYST PHARMAC EC US14888U1016 61,744 -10,690 -14.76 722 -25.90 0.0026
2023-08-28 2023-06-30 NP CATALYST PHARMAC EC US14888U1016 72,434 8,606 13.48 974 -8.03 0.0033
2023-05-26 2023-03-31 NP CATALYST PHARMAC EC US14888U1016 63,828 473 0.75 1,058 -10.19 0.0039
2023-03-01 2022-12-31 NP CATALYST PHARMAC EC US14888U1016 63,355 0 0.00 1,178 45.07 0.0046
2022-11-29 2022-09-30 NP CATALYST PHARMAC EC US14888U1016 63,355 -855 -1.33 813 80.44 0.0034
2022-08-29 2022-06-30 NP CATALYST PHARMAC EC US14888U1016 64,210 0 0.00 450 -15.41 0.0018
2022-05-31 2022-03-31 NP CATALYST PHARMAC EC US14888U1016 64,210 -6,510 -9.21 532 11.30 0.0017
2022-03-01 2021-12-31 NP CATALYST PHARMAC EC US14888U1016 70,720 -16,843 -19.24 479 3.02 0.0013
2021-11-29 2021-09-30 NP CATALYST PHARMAC EC US14888U1016 87,563 0 0.00 464 -7.75 0.0013
2021-08-30 2021-06-30 NP CATALYST PHARMAC EC US14888U1016 87,563 -1,233 -1.39 503 22.98 0.0014
2021-06-01 2021-03-31 NP CATALYST PHARMAC EC US14888U1016 88,796 0 0.00 409 38.18 0.0012
2021-03-01 2020-12-31 NP CATALYST PHARMAC EC US14888U1016 88,796 -33,304 -27.28 297 -18.23 0.0009
2020-11-27 2020-09-30 NP CATALYST PHARMAC EC US14888U1016 122,100 0 0.00 363 -35.82 0.0009
2020-08-31 2020-06-30 NP CATALYST PHARMAC EC US14888U1016 122,100 0 0.00 564 20.00 0.0015
2020-06-01 2020-03-31 NP CATALYST PHARMAC EC US14888U1016 122,100 -2,386 -1.92 470 0.86 0.0015
2020-02-28 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 124,486 -1,140 -0.91 467 -30.13 0.0011
2019-11-27 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 125,626 125,626 667 0.0017
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.